Enfortumab vedotin-ejfv (ADC)
Enfortumab vedotin-ejfv is an ADC consisting of a Nectin-4-directed antibody and Monomethyl auristatin E (MMAE), suitable for adult patients with locally advanced or metastatic urothelial carcinoma, or who have received programmed cell death protein 1 (PD-1) inhibitor or programmed cell death ligand 1 (PD-L1) inhibitor therapy or neoadjuvant/adjuvant platinum-based chemotherapy for locally advanced or metastatic cancer.
Product Specifications
Product Name Alternative
Padcev, ASG-22ME
Reactivity
Human
Applications
Research Grade Biosimilar
Stability
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks) . Store at -20°C 12 months. Store at -80°C long term.
Endotoxin
Please contact with the lab for this information.
Purity
>90% as determined by SEC.
Form
Liquid
Notes
For research use only. Not suitable for clinical or therapeutic use.
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
HE2-HP2E3-25tests 25 Tests
PE-Labeled Human Her2 / ErbB2 Protein, His Tag (Site-specific conjugation)
Ask
View Details 
